Drug intelligence / Profile preview

benzyl nicotinate

Development stage: Unknown
Modality: Small Molecules
Administration: Topical

Overview

Benzyl nicotinate is a small molecule vasodilator and rubefacient. It is the benzyl ester of nicotinic acid (niacin), formed by the condensation of the carboxy group of nicotinic acid with benzyl alcohol. Benzyl nicotinate is primarily used in topical preparations—often in combination with analgesics—for the treatment of muscle, joint, and ligament pain. Its mechanism involves local vasodilation and increased blood flow to the skin when applied topically. It has also been used in creams, baths, and emulsions for both human and veterinary medicine[1][2][5][8].

Other names: benzyl nicotinatenicotinic acid benzyl esterphenylmethyl 3-pyridinecarboxylatephenylmethyl3-pyridinecarboxylatephenylmethyl-3-pyridinecarboxylatebenzyl pyridine-3-carboxylate

Beyond the preview

Go deeper on benzyl nicotinate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on benzyl nicotinate.

Explore the full profile